Abu Bakar Hafeez Bhatti1, Ali Akbar2, Shahid Khattak2, Ather Saeed Kazmi3, Aarif Jamshed4, Aamir Ali Syed2. 1. Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. Electronic address: abubakar.hafeez@yahoo.co. 2. Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. 3. Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. 4. Department of Radiation Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
Abstract
BACKGROUND: Rarely, patients with pathological complete response (PCR) after neoadjuvant chemoradiotherapy demonstrate acellular mucin pools. The prognostic significance of this finding is controversial. The objective of this study was to determine impact of acellular mucin pools on disease free and overall survival in patients with complete pathological response to neoadjuvant chemoradiotherapy in rectal cancer. METHODS: One hundred and seventy two patients received neoadjuvant chemoradiotherapy for rectal cancer and underwent surgery. Patients were divided into two groups based on presence of acellular mucin pools. Locoregional failures, distant failures and deaths were compared. Expected 5 year disease free and overall survival was calculated. RESULTS: Median follow-up was 36(4-94) months. Complete pathological response was identified in 35(20.3%) patients. Of these, 12(34.2%) had acellular mucin pools in resected specimen. Majority of mucin negative tumors were moderately differentiated (78% vs 25%) (P = 0.005). Median overall survival for mucin positive and mucin negative tumors was 4(1.3-5.7) and 3.3(0.1-6.3) years respectively. Expected 5 year disease free and overall survival for mucin positive and mucin negative tumors was 73% and 89% (P = 0.1) and 75% and 87% (P = 0.4). CONCLUSION: Acellular mucin pools in rectal cancer following a PCR to neoadjuvant treatment do not impact survival.
BACKGROUND: Rarely, patients with pathological complete response (PCR) after neoadjuvant chemoradiotherapy demonstrate acellular mucin pools. The prognostic significance of this finding is controversial. The objective of this study was to determine impact of acellular mucin pools on disease free and overall survival in patients with complete pathological response to neoadjuvant chemoradiotherapy in rectal cancer. METHODS: One hundred and seventy two patients received neoadjuvant chemoradiotherapy for rectal cancer and underwent surgery. Patients were divided into two groups based on presence of acellular mucin pools. Locoregional failures, distant failures and deaths were compared. Expected 5 year disease free and overall survival was calculated. RESULTS: Median follow-up was 36(4-94) months. Complete pathological response was identified in 35(20.3%) patients. Of these, 12(34.2%) had acellular mucin pools in resected specimen. Majority of mucin negative tumors were moderately differentiated (78% vs 25%) (P = 0.005). Median overall survival for mucin positive and mucin negative tumors was 4(1.3-5.7) and 3.3(0.1-6.3) years respectively. Expected 5 year disease free and overall survival for mucin positive and mucin negative tumors was 73% and 89% (P = 0.1) and 75% and 87% (P = 0.4). CONCLUSION: Acellular mucin pools in rectal cancer following a PCR to neoadjuvant treatment do not impact survival.
Authors: Franck Housseau; Robert A Anders; Nicolas J Llosa; Brandon Luber; Nicholas Siegel; Anas H Awan; Teniola Oke; Qingfeng Zhu; Bjarne R Bartlett; Laveet K Aulakh; Elizabeth D Thompson; Elizabeth M Jaffee; Jennifer N Durham; Cynthia L Sears; Dung T Le; Luis A Diaz; Drew M Pardoll; Hao Wang Journal: Cancer Immunol Res Date: 2019-08-22 Impact factor: 11.151
Authors: Hedde D Biesma; Tanya T D Soeratram; Karolina Sikorska; Irene A Caspers; Hendrik F van Essen; Jacqueline M P Egthuijsen; Aart Mookhoek; Hanneke W M van Laarhoven; Mark I van Berge Henegouwen; Marianne Nordsmark; Donald L van der Peet; Fabienne A R M Warmerdam; Maud M Geenen; Olaf J L Loosveld; Johanneke E A Portielje; Maartje Los; Daniëlle A M Heideman; Elma Meershoek-Klein Kranenbarg; Henk H Hartgrink; Johanna van Sandick; Marcel Verheij; Cornelis J H van de Velde; Annemieke Cats; Bauke Ylstra; Nicole C T van Grieken Journal: Gastric Cancer Date: 2022-02-07 Impact factor: 7.701